Cover Story
Relying largely on maturing data from the European trials of screening for prostate cancer, the U.S. Preventive Services Task Force has given a better grade—a “C”—to screening for prostate cancer.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
Trending Stories
- Beyond the $500B Stargate Project: The frontier of AI in oncology beckons
- Trump 2016: A look back at the 45th president’s impact on oncology
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - Felix Feng, GU cancer researcher who made fundamental discoveries in genomics, dies at 48
- Pediatric cancer research cut from spending legislation at last minute
Republicans quietly removed hard-won pediatric cancer bills - Rooting out the “illegal and immoral discrimination” of DEI is the first order of business for Trump